After the positive results provided by the clinical trial evaluating novel DMT effects on patients with Major Depressive Disorder MDD psychedelics biotech Small Pharma Inc. DMTTF is updating its IP portfolio following the US Patent and Trademark Office USPTO s notice of allowance to file a patent application covering composition of matter, therapeutic compositions and uses of a group of deuterated DMT compounds.
The USPTO will grant the company a patent protecting composition of matter for certain deuterated homologs of certain tryptamine compounds, including the active ingredients being tested in the SPL 029 oral tryptamine series, as well as the therapeutic compositions of the deuterated tryptamines, including orally active formulations.
See also: Cybin Approved For First In-Human Dosing Of DMT Molecule CYB 004, Milestone For Anxiety Disorder Treatment
Small Pharma's multi-layered patent strategy targets key areas of protection across its research and development pipeline.
For SPL 026, this includes an optimized injectable formulation for extended shelf life and a synthetic, Good Manufacturing Process GMP compliant route. For pipeline candidate SPL 028 and the SPL 029 series, protection on the composition of the deuterated compounds as well as their medical use and therapeutic composition is also provided by the pipeline candidate SPL 028 and the SPL 029 series.
CEO George Tziras said that innovation on known compounds was the foundation of Small Pharma's vision, and they continue to explore ways to optimize their assets in order to maximize their clinical and commercial potential. Tziras said that building a robust IP position is essential to protecting these innovations and allowing pipeline programs to work toward developing a proprietary position in key markets such as the U.S. and Europe.
Photo: Benzinga edit with photo by CDC on Pexels and Jynto on Wikimedia Commons.